Tamara Rothenburger
Overview
Explore the profile of Tamara Rothenburger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bojkova D, Bechtel M, Rothenburger T, Kandler J, Hayes L, Olmer R, et al.
J Med Virol
. 2023 Mar;
95(3):e28686.
PMID: 36938992
Recent findings in permanent cell lines suggested that SARS-CoV-2 Omicron BA.1 induces a stronger interferon response than Delta. Here, we show that BA.1 and BA.5 but not Delta induce an...
2.
Bojkova D, Zoller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, et al.
J Med Virol
. 2023 Mar;
95(3):e28652.
PMID: 36897017
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited...
3.
Bojkova D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler J, et al.
iScience
. 2023 Jan;
26(2):105944.
PMID: 36644320
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for monitoring the replication of SARS-CoV-2 isolates from...
4.
Bojkova D, Bechtel M, Rothenburger T, Steinhorst K, Zoller N, Kippenberger S, et al.
N Engl J Med
. 2022 Dec;
388(3):279-281.
PMID: 36577096
No abstract available.
5.
Bojkova D, Stack R, Rothenburger T, Kandler J, Ciesek S, Wass M, et al.
J Infect
. 2022 Aug;
85(5):573-607.
PMID: 35917841
No abstract available.
6.
Bojkova D, Rothenburger T, Ciesek S, Wass M, Michaelis M, Cinatl Jr J
Cell Discov
. 2022 May;
8(1):42.
PMID: 35538050
No abstract available.
7.
Rothenburger T, Thomas D, Schreiber Y, Wratil P, Pflantz T, Knecht K, et al.
J Exp Clin Cancer Res
. 2021 Oct;
40(1):317.
PMID: 34641952
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1...
8.
Rothenburger T, McLaughlin K, Herold T, Schneider C, Oellerich T, Rothweiler F, et al.
Commun Biol
. 2020 Jun;
3(1):324.
PMID: 32581304
The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), is effective against T-cell acute lymphoblastic leukaemia (T-ALL) but not against B-cell ALL (B-ALL). The underlying mechanisms have remained elusive. Here,...
9.
Oellerich T, Schneider C, Thomas D, Knecht K, Buzovetsky O, Kaderali L, et al.
Nat Commun
. 2019 Aug;
10(1):3475.
PMID: 31375673
Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA...